About Us

The foundation was laid with the inclusion of RA Chem Pharma, known for its strong footprint in APIs, intermediates, and finished dosage formulations…setting the tone for a platform focused on quality and scientific depth.

With the addition of ZCL Chemicals, the platform expanded its capability in complex intermediates, enhancing its ability to serve global pharmaceutical innovators.

The journey progressed with Avra, bringing expertise in high-complexity chemistry and ADC payloads – positioning the platform to support next-generation therapeutics.

Suven Pharmaceuticals, with its rich heritage in CRAMS and custom synthesis, joined hands with the growing platform. This marked a pivotal point where the vision of Cohance – a differentiated, technology-led CDMO platform – began to take shape.

While the Cohance–Suven integration was underway, the platform advanced further with Sapala Organics (bringing oligonucleotide capabilities) and NJ Bio (offering end-to-end integrated ADC services), broadening scientific reach in novel modalities.

With the integration of capabilities from all its constituents, the combined entity moves forward as Cohance Lifesciences Limited – a fully integrated, innovation-led partner to global pharma companies, spanning CDMO, APIs, specialty chemicals, and FDF.